Science Advisory Board

Professor Paul Herrling was Chairman of the Board of the Novartis Institute for Tropical Diseases in Singapore, an endeavor to advance medical research in the area of tropical infectious diseases, which historically have received little drug-research funding. Prior to this, he previously held the roles of Head of Corporate Research and Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC), he was a member of the Board of the Genomics Institute of the Novartis Research Foundation in La Jolla California, and he served on the boards of several other research institutions most notably he was Vice President of the Board of the Swiss Federal Institutes of Technology (ETH Board). He is currently Secretary of the Board of Drugs for Neglected Diseases Initiative (DNDi), an NGO in Geneva. He is also Professor emeritus of Drug Discovery Science at the University of Basel, Switzerland. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA).